Abstract:Background This study aimed to determine whether community-acquired pneumonia (CAP) had a metabolic profile and whether this profile can be used for disease severity assessment. Methods A total of 175 individuals including 119 CAP patients and 56 controls were enrolled and divided into two cohorts. Serum samples from a discovery cohort ( n = 102, including 38 non-severe CAP, 30 severe CAP, and 34 age and sex-matched controls) were determined by untargeted ultra-high-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS)-based metabolomics. Selected differential metabolites between CAP patients versus controls, and between the severe CAP group versus non-severe CAP group, were confirmed by targeted mass spectrometry assays in a validation cohort ( n = 73, including 32 non-severe CAP, 19 severe CAP and 22 controls). Pearson’s correlation analysis was performed to assess relationships between the identified metabolites and clinical severity of CAP. The area under the curve (AUC), sensitivity and specificity of the metabolites for predicting the severity of CAP were also investigated. Results The metabolic signature was markedly different between CAP patients and controls. Fifteen metabolites were found to be significantly dysregulated in CAP patients, which were mainly mapped to the metabolic pathways of sphingolipid, arginine, pyruvate and inositol phosphate. The alternation trends of five metabolites among the three groups including sphinganine, p-Cresol sulfate, dehydroepiandrosterone sulfate (DHEA-S), lactate and l -arginine in the validation cohort were consistent with those in the discovery cohort. Significantly lower concentrations of sphinganine, p-Cresol sulfate and DHEA-S were observed in CAP patients than in controls ( p < 0.05). Serum lactate and sphinganine levels were positively correlated with confusion, urea level, respiratory rate, blood pressure, and age > 65 years (CURB-65), pneumonia severity index (PSI) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, while DHEA-S inversely correlated with the three scoring systems. Combining lactate, sphinganine and DHEA-S as a metabolite panel for discriminating severe CAP from non-severe CAP exhibited a better AUC of 0.911 (95% confidence interval 0.825–0.998) than CURB-65, PSI and APACHE II scores. Conclusions This study demonstrates that serum metabolomics approaches based on the LC-MS/MS platform can be applied as a tool to reveal metabolic changes during CAP and establish a metabolite signature related to disease severity. Trial registration ClinicalTrials.gov, NCT03093220 . Registered retrospectively on 28 March 2017.

Longitudinal metabolite profiling of Streptococcus pneumoniae-associated community-acquired pneumonia

N-Myc and STAT Interactor is a Novel Biomarker of Severity in Community-Acquired Pneumonia: A Cohort Study

Metabolic profiles in community-acquired pneumonia: developing assessment tools for disease severity

Serum metabolomics profile identifies patients with community-acquired pneumonia infected by bacteria, fungi, and viruses

Metabolic inventory of Streptococcus pneumoniae growing in a chemical defined environment

Proteomic profiling of neutrophils and plasma in community-acquired pneumonia reveals crucial proteins in diverse biological pathways linked to clinical outcome

Lipid Profiles and Differential Lipids in Serum Related to Severity of Community-Acquired Pneumonia: A Pilot Study

A molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admission

Plasma proteome analysis and validation of patients with community‐acquired pneumonia: A cohort study

Lipid Profile and Differential Lipids in Serum Predict Severity of Community-Acquired Pneumonia: A Prospective, Multi-Centre Study

Transitions in lung microbiota landscape associate with distinct patterns of pneumonia progression

Biomarkers: Are They Useful in Severe Community-Acquired Pneumonia?

A multicenter prospective study of comprehensive metagenomic and transcriptomic signatures for predicting outcomes of patients with severe community-acquired pneumonia

LSC Abstract – Systemic and Local Metabolomics Profiling Reveals Novel Insights into the Progression of Emphysema

Serum Metabolite Profiles As Potential Biochemical Markers In Young Adults With Community-Acquired Pneumonia Cured By Moxifloxacin Therapy

Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population

Comparative Analysis of the Host Response to Community-acquired and Hospital-acquired Pneumonia in Critically Ill Patients

Inflammatory responses relate to distinct bronchoalveolar lavage lipidome in community-acquired pneumonia patients: a pilot study

Serum-integrated omics reveal the host response landscape for severe pediatric community-acquired pneumonia

Targeted Lipidomics Reveals Phospholipids and Lysophospholipids As Biomarkers for Evaluating Community-Acquired Pneumonia

A cross-omics integrative study of metabolic signatures of chronic obstructive pulmonary disease